Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 28 for “"Deferasirox"”.
-
A role for deferasirox as an anti-neoplastic and chemosensitising agent in gastrointestinal cancer
… cells of iron using the licensed iron chelator Deferasirox was effective in the treatment of oesophageal and colorectal cancer. Deferasirox significantly impedes cellular viability and proliferation both \(in-vitro\) and \(in-vivo\) in oesophageal and colorectal cancer models. The drug can …
-
Efficacy of Deferasirox in Preventing Complications of Iron Overload in the Iron Overloaded Gerbil
… orally effective, iron chelating agent deferasirox is thought to offer tremendous promise as an alternative to deferoxamine. However, the efficacy and safety profile of deferasirox is not yet clear. In the present study, the efficacy of deferasirox in removing iron from target tissues …
-
Influência do ferro no crescimento e na suscetibilidade ao itraconazol e deferasirox em Sporothrix spp
… para o seu desenvolvimento e o quelante de ferro deferasirox tem demonstrado atividade contra certos fungos patogênicos. Objetivo: O presente estudo avaliou o crescimento e a suscetibilidade ao estresse oxidativo de Sporothrix spp. in vitro quando exposto a diferentes concentrações de ferro e sua …
-
The development of hexaphyrin-expanded porphyrins and deferasirox derivatives for their applications toward f-element coordination
Expanded porphyrins are versatile ligands that allow a multitude of coordination modes. Modification of the porphyrin core and the pendant substituents have extended the coordination chemistry of expanded porphyrins to include systems that stabilize f-element metal complexes. In this dissertation, …
-
Exploration of the iron chelator deferasirox : a multifaceted platform for the development of antineoplastic agents and water-soluble sensors
… derivatization of the clinical iron chelator deferasirox with focus on the preparation of chelators that show enhanced activity against cancer cells. In addition, I have investigated the optimization of deferasirox as chemosensor for Fe³⁺ in water samples. In chapter 1, an overview on the …
-
Ανάπτυξη και επικύρωση μεθόδου Υγροχρωματογραφίας Υδρόφιλης Αλληλεπίδρασης-Φασματομετρίας μαζών για τον ποσοτικό προσδιορισμό του Deferasirox σε ανθρώπινο πλάσμα.
… που κάνουν συχνά μεταγγίσεις αίματος. Το deferasirox, 4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl] benzoic acid, είναι ένας από του στόματος χορηγούμενος χηλικός παράγοντας που χρησιμοποιείται για τη θεραπεία αποσιδήρωσης. Στόχος της παρούσας μελέτης ήταν η …
-
Development and Characterization of Boronate-Masked Prochelators for Peroxide-Triggered Metal Chelation
… salicylaldehyde isonicotinic hydrazone (SIH) and deferasirox, where a boronate masking group blocks metal binding in the resulting “prochelator” until peroxide activation release the parent chelator.</p><p>Based on the aroylhydrazone chelator SIH, our first prochelator BSIH was previously shown to …
-
Ανάπτυξη μεθόδου εκχύλισης προσρόφησης σε υφασμάτινο μέσο με χρήση πειραματικού σχεδιασμού για τον προσδιορισμό του deferasirox σε ανθρώπινο πλάσμα
… που κάνουν συχνά μεταγγίσεις αίματος. Το deferasirox, 4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl] benzoic acid, είναι ένας από του στόματος χορηγούμενος χηλικός παράγοντας που χρησιμοποιείται για τη θεραπεία αποσιδήρωσης σε ασθενείς με β-θαλασσαιμία. Στην …
-
EFFECT OF ENVIRONMENTAL IRON ON GROWTH PATTERNS, BIOFILM FORMATION, AND ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA GLABRATA
… 1.562μM, 1.562μM, and 4μM, as the MIC for Deferasirox, Nystatin, and Fluconazole, respectively. Drug synergy experiments revealed a 128-fold reduction in the amount of Nystatin and Fluconazole needed, with the addition of 1/8th of Deferasirox concentration. The biofilm experiments were …
-
Zelluläre Charakterisierung neuer Hemmstoffe der Jumonji C-Domäne-enthaltenden Demethylasen
… führt. Die zugelassenen Eisenchelatoren Deferasirox und Deferoxamin inhibieren JmjC-Demethylasen der KDM4-Subfamilie in Krebszelllinien und haben eine antiproliferative Wirkung auf die Zellen. In unserer Arbeitsgruppe entwickelte Derivate des Deferasirox sind im Hinblick auf die mittlere …
-
Μελέτη της ποιότητας ζωής και εφαρμογή θεραπευτικών μεθόδων σε ασθενείς που πάσχουν απο β-θαλασσαιμία στη Δυτική Ελλάδα
… older. In addition, patients, whose ICT included deferasirox were estimated to have an 11.4-point higher MCS score, than patients not receiving deferasirox (borderline non-significance; p=0.051), and higher SF-36 Bodily Pain domain score (mean score: 81.3 versus 71.6; p=0.050). In their majority, …
-
Synthesis and testing of inhibitors for jumonjiC domain-containing histone demethylases
… analogs of the clinically approved iron-chelator deferasirox. The first approach yielded two scaffolds with IC50 values in the micromolar range, which both contain tetrazoles as bioisosteric replacement for carboxylic acids. The second approach resulted in five different core structures – …
-
Μελέτη της αιμοσιδήρωσης σε μη-μεταγγιζόμενους ασθενείς με μεσογειακά σύνδρομα: τρόποι θεραπείας και συσχέτιση με κλινικό φαινότυπο και άλλους επιβαρυντικούς παράγοντες
… with serum ferritin> 450mg/L the new chelator Deferasirox was orally administered, at doses of 10 or 20 mg/kg BW based on serum ferritin value. Treatment success was evaluated after a year’s time based on the reduction of serum ferritin, the reduction of liver iron concentration (LIC) by 3mg …
-
Διερεύνηση του ρόλου του οξειδωτικού στρες και της ομοιοστασίας του σιδήρου σε παθολογικές καταστάσεις
… iron. It was shown that deferiprone and deferasirox, contrary to desferrioxamine and caffeic acid, had the capacity to chelate intracellular iron and to protect the cellular DNA against H2O2-induced damage. Following, deferiprone, deferasirox and caffeic acid had the ability to donate …
-
Συμβολή στην μελέτη πρόσθιου και οπίσθιου λαβύρινθου σε ασθενείς με β-μεσογειακή αναιμία
… .5th) The combination deferoxamine with deferasirox or monotherapy with deferasirox in patients withgood chelation, causes most hearing loss at high frequencies, that the combination of deferoxamine withdeferiprone.6th) we identified simple equations that allow us to adjust the dose of …
-
Non-absorbable iron chelators for the treatment of colorectal cancer
… of this cancer. A clinically used iron chelator deferasirox and a modified version of this ligand, were attempted to be conjugated onto biopolymers chitosan and alginate. These non-absorbable polymers were hypothesised to be undigested in the gastrointestinal tract, thus specifically capable of …
-
Assays and Inhibitors for JumonjiC Domain-Containing Histone Demethylases as Epigenetic Regulators
… manner. Clinically used iron chelators like deferasirox and novel synthetic analogs potently inhibited demethylases in vitro and in vivo in a broad range of esophageal cancer cells with on-target effects on cellular histone methylation levels.<br>These novel lead structures are valuable tool …
-
Ηλεκτροφυσιολογική μελέτη οφθαλμών σε ασθενείς με βήτα μεσογειακή αναιμία
… therapy with deferoxamine (group A, n = 13), deferasirox (group B, n = 11) or deferoxamine with deferiprone (group C, n = 14) and fourteen age- and sex- matched healthy individuals were included in the study. All participants underwent ophthalmoscopy, full-field electroretinography (ERG), …
Page 1 of 2